| Autor: |
Fernández-Sánchez A; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., Hernández-Sánchez A; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., De Ramón C; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., Chillón MC; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., Vidriales MB; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., Baile-González M; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., Fuentes-Morales CT; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., Sierra-Pacho M; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., López-Corral L; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain., Sánchez-Guijo F; Hematology Department, IBSAL-University Hospital of Salamanca, Department of Medicine and Cancer Research Center (CIC), University of Salamanca, 37007 Salamanca, Spain. |
| Abstrakt: |
The advent of tyrosine kinase inhibitors (TKIs) has changed the natural history of chronic myeloid leukemia (CML), and the transformation from the chronic phase to the blast phase (BP) is currently an uncommon situation. However, it is one of the major remaining challenges in the management of this disease, as it is associated with dismal outcomes. We report the case of a 63-year-old woman with a history of CML with poor response to imatinib who progressed to myeloid BP-CML, driven by the acquisition of t(8;21)(q22;q22)/ RUNX1::RUNX1T1 . The patient received intensive chemotherapy and dasatinib, followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, she suffered an early relapse after allo-HSCT with the acquisition of the T315I mutation in ABL1 . Ponatinib and azacitidine were started as salvage treatment, allowing for the achievement of complete remission with deep molecular response after five cycles. Advances in the knowledge of disease biology and clonal evolution are crucial for optimal treatment selection, which ultimately translates into better patient outcomes. |
